Physician profile
Johnathan Vu
NPI 1518348721
$2,602.82
in general payments reported to CMS, 2019-2025
30 companies · $1,044 in 2025
The $1,044 reported for 2025 was more than what 94% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $229 · 2021: $98.76 · 2022: $515 · 2023: $335 · 2024: $381 · 2025: $1,044.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,759.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,759.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $315.99 | 2021-2025 | Nayzilam, Rystiggo |
| Pacira Pharmaceuticals Incorporated | $217.74 | 2022-2023 | Exparel |
| Si-Bone, INC. | $167.52 | 2022 | |
| Neurelis, INC. | $159.10 | 2023-2025 | Valtoco |
| Abbvie INC. | $154.71 | 2023-2025 | Botox |
| Merck Sharp & Dohme LLC | $134.53 | 2019-2023 | Bridion |
| Avanos Medical | $123.97 | 2022 | |
| Saluda Medical Americas, INC. | $119.11 | 2025 | Evoke |
| Lundbeck LLC | $118.50 | 2024-2025 | Vyepti, Rexulti |
| Boston Scientific Corporation | $107.81 | 2019-2025 | Intracept |
| Mallinckrodt Enterprises LLC | $105.61 | 2019 | |
| Sk Life Science, INC. | $100.61 | 2024 | |
| Tg Therapeutics, INC. | $97.90 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $81.48 | 2023-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $74.99 | 2022-2025 | Austedo Xr, Austedo Xr |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $66.06 | 2021-2025 | Vumerity, Tysabri |
| Argenx US, INC. | $65.89 | 2023-2025 | Vyvgart Hytrulo |
| Alexion Pharmaceuticals, INC. | $60.58 | 2024-2025 | Ultomiris |
| Eisai INC. | $47.71 | 2023-2024 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $46.70 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $33.24 | 2021 | |
| Axsome Therapeutics, INC. | $33.02 | 2025 | Symbravo |
| Alnylam Pharmaceuticals INC. | $26.92 | 2025 | Onpattro |
| Vertex Pharmaceuticals Incorporated | $24.03 | 2025 | |
| Appliedvr INC | $23.48 | 2025 | Relievrx |
| Lilly USA, LLC | $23.23 | 2025 | Kisunla |
| Pfizer INC. | $19.79 | 2024 | |
| Nevro Corp. | $18.64 | 2024 | Senza |
| Impel Pharmaceuticals LLC | $18.15 | 2025 | Trudhesa |
| Collegium Pharmaceutical, INC. | $15.81 | 2025 | Belbuca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Johnathan Vu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.